Go to deals
Healthcare

Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.

The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.

Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.

Parties

Talk to the deal team

Paul R. Smolevitz

Managing Director
New York, United States
Oaklins TM Capital

James McLaren

Managing Director
New York, United States
Oaklins TM Capital

Vidur Kapur

Associate Director
New York, United States
Oaklins TM Capital

Related deals

Bayer AG has entered into a takeover agreement with Cara Care
Healthcare | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Learn more
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
Healthcare

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Learn more
Springwell Veterinary Surgery has been transferred to an Employee Ownership Trust
Consumer & Retail | Healthcare

Springwell Veterinary Surgery has been transferred to an Employee Ownership Trust

Springwell Veterinary Surgery has become employee owned after transferring into an Employee Ownership Trust (EOT).

Learn more